BRENDA ACOSTA: Open Payments
NPI 1871369728 · YAKIMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,578 in 85 payments from 8 companies in 2025. Trend: 2023 $159 · 2024 $604 · 2025 $1,578
Food & beverage: $1,578
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 5 | $361 |
| Janssen Pharmaceuticals, Inc | 8 | $334 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $194 |
| Neurocrine BioSciences, Inc. | 3 | $172 |
| Otsuka America Pharmaceutical, Inc. | 27 | $157 |
| Teva Pharmaceuticals USA, Inc. | 9 | $153 |
| Axsome Therapeutics, Inc. | 4 | $150 |
| Alkermes, Inc. | 3 | $58 |
Products named: COBENFY, INVEGA SUSTENNA, CAPLYTA, INGREZZA, Auvelity, UZEDY, REXULTI, ABILIFY MAINTENA.
Industry payments across WA — which companies pay providers there.
